Biocure Technology Inc. announced that it has entered into an exclusive letter agreement with Atriva Therapeutics GmbH which has issued common shares of the company for the aggregate gross proceeds of $15,000,000 on September 18, 2023. The securities of the company have not been and will not be registered under the United States Securities Act of 1933, as amended.